Amgen's Phase 3 MariTide OSA trial status update: active, not recruiting
Amgen's registry record for MARITIME-OSA-2, testing maridebart cafraglutide in obstructive sleep apnea, was updated to show the trial no longer recruiting.
This week's filing covers a single update to an Amgen Phase 3 trial record.
- Amgen's Phase 3 study MARITIME-OSA-2 is evaluating maridebart cafraglutide against placebo over 52 weeks in adults with obstructive sleep apnea who are not on PAP therapy and are living with overweight or obesity.1 The record, first posted November 10, 2025, was last updated September 29, 2026, and now lists the trial as active but not recruiting, with an estimated enrollment of 250 participants.1 The primary outcome is change in Apnea-hypopnea Index (AHI) from baseline at Week 52.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.